Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||FATE-NK100 + Trastuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|FATE-NK100||FATE-NK100 are donor-derived natural killer cells, which may induce cell death, and result in increased generation of inflammatory cytokines, thereby mediating an immune response against cancer cells (Cancer Res 2017;77(13 Suppl):Abstract nr 3752).|
|Trastuzumab||Herceptin||Anti HER2||HER2 (ERBB2) Antibody 38||Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03319459||Phase I||FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100||FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors||Active, not recruiting|